Understanding CancelRx: Results of End-to-End Functional Testing, Proactive Risk Assessment, and Pilot Implementation

Samantha I. Pitts¹  Noah Barasch²  Andrew T. Maslen³  Bridgette A. Thomas⁴  Leonard P. Dorissaint³  Krista G. Decker⁵  Sadaf Kazi²  Yushi Yang⁶  Allen R. Chen⁷

¹Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, Maryland, United States
²Armstrong Institute for Patient Safety and Quality, Johns Hopkins University School of Medicine, Baltimore, Maryland, United States
³Information Technology, Johns Hopkins Health System, Baltimore, Maryland, United States
⁴Pharmacy Services, Johns Hopkins Home Care Group, Baltimore, Maryland, United States
⁵Department of Quality Management, Johns Hopkins Home Care Group, Baltimore, Maryland, United States
⁶Armstrong Institute for Patient Safety and Quality, Johns Hopkins Health System, Baltimore, Maryland, United States
⁷Departments of Oncology and Pediatrics, Johns Hopkins University School of Medicine, Baltimore, Maryland, United States

Address for correspondence Samantha I. Pitts, MD, MPH, Department of Medicine, Johns Hopkins University School of Medicine, 1830 East Monument Street, Room 8020, Baltimore, MD 21287, United States (e-mail: Spitts4@jhmi.edu).


Abstract

Background  CancelRx allows prescribers to send electronic cancellation messages to pharmacies when medications are discontinued. Little is known about its functionality and impact on clinical workflows.

Objectives  To understand CancelRx functionality, its potential impact on workflows and medication safety risks, and to develop mitigating strategies for risks introduced by implementation.

Methods  We conducted direct observations and semi-structured interviews to develop CancelRx use cases and assessed CancelRx in an end-to-end test environment, proactive risk assessment, and pilot implementation from April 16 to July 15, 2018.

Results  E-cancellations were sent upon discontinuation of e-prescriptions written within the electronic health record (EHR), but not other medications (e.g., printed prescriptions) and could be initiated by nonprescribers. In our proactive risk assessment, CancelRx implementation eliminated five of seven failure modes in outpatient prescribing to Johns Hopkins pharmacies, but introduced new risks, including (1) failure to act if an e-cancellation was not sent or was unsuccessful; (2) failure to cancel all prescriptions for a medication; (3) errors in manual matching; and (4) erroneous medication cancellations. We identified potential mitigation strategies for these risks. During pilot implementation, 92.4% (428/463) of e-cancellations had confirmed approval by the receiving pharmacy, while 4.5% (21/463) were denied, and 3.0% (14/463) had no e-cancellation response. Among e-cancellations received by the pilot pharmacy, 1.7% (7/408) required manual matching by pharmacy staff. Based on

Keywords
► electronic prescribing
► medication errors
► risk assessment

This document was downloaded for personal use only. Unauthorized distribution is strictly prohibited.
performance in testing, 73.4% (340/463) of completed e-cancellations would be expected to generate an in-basket message, including 21 (6.2%) denials and 319/340 (93.8%) approvals with a note from the pharmacy.

**Conclusion**  CancelRx is an important functionality with the potential to decrease adverse events due to medication errors. However, changes in implementation in our EHR and pharmacy software and enhancements in the CancelRx standard are needed to maximize safety and usability. Further studies are needed to evaluate the impact of e-cancellation on medication safety.

**Background and Significance**

Adverse drug events (ADE) are frequent in ambulatory care, leading to an estimated 4.5 million patient visits each year. Medication errors are a leading cause of preventable ADE and patient harm in ambulatory settings. Although computerized provider order entry with clinical decision support can decrease medication errors, there is increasing recognition of safety risks associated with electronic prescribing.

Safe prescribing in ambulatory care is a complex process that entails coordination among multiple stakeholders, including prescribers, pharmacy staff, and patients. The vast majority of prescriptions in the United States are now sent electronically from electronic health records (EHRs), through an intermediary, most commonly Surescripts, to pharmacies. However, most EHRs do not currently notify pharmacies when prescribers discontinue or change medications; instead, prescribers are expected to call or fax pharmacies to communicate this information. An analysis of a sample of new e-prescriptions identified messages to discontinue another prescription in 0.7% of transactions, or an estimated 10 million e-prescriptions annually, which likely represents a small fraction of medication discontinuations.

Failure to communicate medication changes to pharmacies is a significant contributing factor to medication errors and preventable ADE; without communication, an estimated 1.5 to 5% of prescriptions are filled after intended discontinuation by a clinician. Erroneous continuation of these medications, including duplicate therapies and medications prescribed in error, has led to serious adverse events, including clinically significant drug side effects and inadequate supply of critical medications, contributing to hospital admissions. Improved communication between prescribers and pharmacies, including electronic communication of medication discontinuation, is a critical safety priority.

The National Council for Prescription Drug Programs’ SCRIPT standard (version 10.6) for e-prescribing supports a functionality called CancelRx, which allows prescribers to send electronic cancellation messages, or “e-cancellations”, through Surescripts or another intermediary to pharmacies when medications are discontinued or changed. The importance of CancelRx for safe e-prescribing has been recognized by multiple stakeholders. Despite the availability of CancelRx in the SCRIPT standard since 2010, adoption has been limited. The Medicare Access and CHIP Reauthorization Act of 2015 (MACRA) required EHRs to include electronic cancellation messaging to pharmacies, but prescribers and pharmacies must also certify their capacity to handle CancelRx messages. While the number of CancelRx transactions on the Surescripts network is increasing, the impact of CancelRx on the workflow of key stakeholders and patient outcomes remains largely unknown.

Similar to some other large health systems, Johns Hopkins uses two different information technology systems for its EHR (Epic, Verona, Wisconsin, United States) and outpatient pharmacy management software (EnterpriseRx, v. 8.0.0.6 and 8.3.0.5, McKesson Corporation, San Francisco, California, United States). As a result, e-prescriptions written by Johns Hopkins clinicians are transmitted externally through the Surescripts network to Johns Hopkins outpatient pharmacies, using the same exact mechanism as external pharmacies. In the absence of CancelRx, Johns Hopkins outpatient pharmacies were not automatically notified of medication changes made by Johns Hopkins clinicians, leading to potential dispensing errors and ADEs. Given the likely benefit but limited understanding of CancelRx functionality and the multiple stakeholders involved in implementation, we sought to understand the impact of CancelRx on workflows and medication safety risks to inform safe implementation of CancelRx at Johns Hopkins.

**Objectives**

The objectives of this study were (1) to understand CancelRx functionality and its potential impact on the workflows of key stakeholders in ambulatory care; (2) to assess the potential impact of CancelRx on safety risks related to communication of medication discontinuation; and (3) to develop mitigating strategies for remaining risks in communication of medication discontinuation and those introduced by CancelRx implementation.

**Methods**

Our primary study team included the Johns Hopkins Medicine Health Information Technology (HIT) Safety Officer (A. R.C.), HIT leads from Epic ambulatory (A.T.M. and L.P.D.) and pharmacy (B.A.T.), a pharmacy safety officer (K.G.D.), a human factors psychologist (S.K.) and a human factors engineer (Y.Y.), a HIT Safety project manager (N.B.), and a general internist and ambulatory patient safety researcher.
(S.I.P.). To attain our objectives, we developed a series of use cases for CancelRx, established an end-to-end test environment for functional testing, conducted a proactive risk assessment of medication discontinuation within ambulatory care, and implemented CancelRx in a pilot practice and pharmacy at Johns Hopkins. The Johns Hopkins Bartlett Specialty Practice, an adult infectious disease specialty practice, and the Bartlett Pharmacy were selected due to the close working relationship between the practice and pharmacy, the established safety infrastructure in the practice, including a comprehensive unit based safety program team, and the frequent use of high-risk medications, such as highly active antiretroviral therapy (HAART).²⁴

**Development of Use Cases**

A study team member conducted four direct observations of pharmacy staff to understand their workflows within the pharmacy, and specifically within the EnterpriseRx pharmacy management software. The team member took handwritten notes which were used to create a process map of pharmacy workflows. As observed discontinuations were infrequent, we then conducted 11 semi-structured interviews, including 6 with Bartlett Specialty Practice prescribers and 5 with Bartlett pharmacists and pharmacy technicians to understand current communications and processes around medication discontinuation and changes. Using an interview guide developed by the team, two team members conducted the interviews to identify whether and how prescribers communicated with the pharmacy for five scenarios, including adverse drug reaction, medication written in error, change in medication regimen, change in dose or frequency, or completion of therapy. The interviewer took written notes, which were transcribed for analysis. The study team conducted thematic analysis of the interview notes, guided by the Systems Engineering in Patient Safety (SEIPS) human factors framework. The SEIPS model describes a health care work system in which patients and providers interact using tools (i.e., CancelRx) to perform a task (e.g., discontinue medications) within a work system (i.e., Johns Hopkins) informed by organization and societal context (e.g., regulations, policies).²⁵,²⁶

**Creation of End-to-End Test Environment and Test Scenarios**

In collaboration with Surescripts (Arlington, Virginia, United States), we established an end-to-end test environment which simulated the Johns Hopkins production environment for e-prescribing. In this environment, e-prescription and “e-cancellation” messages could be transmitted via Surescripts from our Epic test environment (2017, Verona, Wisconsin, United States) to our McKesson EnterpriseRx (v. 8.0.0.6 and 8.3.0.5) test environment. We evaluated three stages of CancelRx implementation: (1) transmission of the e-cancellation message; (2) processing of the e-cancellation and response by the pharmacy; and (3) communication of e-cancellation status back to the prescriber.

We developed test scenarios based on the intentions of prescribers and clinical workflows in order to examine e-cancellation under various conditions including: the presence or absence of an e-prescription; whether an e-prescription was active or inactive; the location of the e-prescription in the pharmacy management system; and whether the pharmacy was able to accept e-cancellation messages. To simulate pilot implementation, we used two test prescribers, one with and one without the e-cancellation functionality, and modified the test environment order transmittal rule to restrict the e-cancel functionality to a single pilot practice by evaluating the encounter department of the original e-prescription.

**Proactive Risk Assessment**

We conducted a failure mode and effect analysis to proactively identify potential risks related to medication errors in ambulatory prescribing to Johns Hopkins pharmacies and their severity, frequency, and detectability prior to e-cancellation implementation. We recruited stakeholders, including physicians, nurse practitioners, nurses, pharmacists, and pharmacy technicians across Johns Hopkins to participate with the core team in a series of nine 60 to 90 minute focus groups for the proactive risk assessment. A total of 17 people including the core team participated in at least one of the focus groups. In the initial focus groups, stakeholders reviewed and confirmed the workflows and use cases previously developed by the study team. In subsequent focus groups, stakeholders identified potential medication safety risks in the existing workflow. Participants in the final focus groups were asked to score each failure mode by assigning a likelihood from 1 to 4 to the severity of the associated risk, the frequency of occurrence, and the detectability of an event, with higher scores indicating greater risk, frequency, and difficulty of detection, respectively. We assigned the final score for each based on discussion and consensus. The total score, or risk prediction number, for each failure mode was determined by multiplying these scores (severity × frequency × detectability); higher scores indicate a greater potential risk. The study team then presented the e-cancellation functionality identified from testing of the scenarios in the test environment. The stakeholder focus groups evaluated which existing risks were mitigated by e-cancellation implementation and identified and scored any new medication safety risks.

**Pilot Implementation and Evaluation**

We subsequently implemented e-cancellation with 14 pilot prescribers in the infectious disease specialty practice and pharmacy. Pilot prescribers were given the cancel order/request service level within Epic, and CancelRx was enabled for the pilot pharmacy. As any reorder of a medication results in the discontinuation of the old prescription and generation of a new prescription, we elected to suppress e-cancellation messages for prescriptions that were discontinued when a medication was reordered. As in the test environment, we also updated a portion of the enterprise order transmittal rule in the EHR to have it evaluate the encounter department of the original e-prescription in order to restrict the functionality to the pilot practice.
We analyzed 3 months of transactions following CancelRx implementation (April 16 to July 15, 2018). Our primary outcome was confirmed prescription deletion or deactivation by the pharmacy, measured as the proportion of e-cancellations that resulted in an electronic response indicating approval by the receiving pharmacy. We used an orders report to identify medications that were discontinued in the EHR by pilot prescribers and an EHR interfaces report to identify which of these discontinuations resulted in an e-cancellation. We determined the pharmacy response to the e-cancellation (i.e., approved or denied) using pharmacy management software data for the Johns Hopkins pharmacy and Surescripts data for external pharmacies. If neither were available, we conducted chart review to determine if a pharmacy message was received within Epic.

Secondary outcomes included the proportion of medication discontinuations that generated an e-cancellation, the number of in-basket messages that would be generated, based on performance in the test environment and the response to e-cancellation from the pharmacy, and time to e-cancellation response by pharmacies. Time from e-cancellation to pharmacy response was calculated by Surescripts as the difference in time between the receipt of each message at Surescripts. All analyses were conducted using SAS version 9.4 (SAS Institute Inc., Cary, North Carolina, United States). This study was acknowledged as a quality improvement initiative by the Johns Hopkins School of Medicine Institutional Review Board.

Results

Current Processes and Use Cases

E-prescriptions enter McKesson EnterpriseRx through the Inbound Communications Queue (ICQ) and progress through a series of queues (e.g., data entry, dispensing, and verification) as they are processed by pharmacy staff. Within the pharmacy management software, successful manual cancellation of an unfilled prescription resulted in deletion of the prescription from the patient profile. In contrast, successful manual cancellation of a previously dispensed prescription results in the deactivation of the prescription. The deactivated prescription remains in the patient profile with a status of “discontinued” and cannot be used to initiate a refill request.

At baseline, if communication of medication discontinuation was attempted, prescribers used a variety of methods to communicate with pharmacy staff, including placing a phone call themselves, delegating communication to a staff member who would call or send a fax, sending an in-basket message to a designated pharmacist within the EHR, and using the “note to pharmacy” field on a different prescription. Pharmacy staff confirmed that prescribers would communicate medication changes or discontinuation through a variety of methods, but indicated that prescribers infrequently contacted them. Instead, pharmacists were highly vigilant for errors and would access the EHR directly to clarify patients’ medication regimens, an option unavailable to external pharmacies. Pharmacy staff reported initiating the great majority of communications with prescribers as a result of identification of discrepancies.

We created a framework to understand prescriber intentions, reasons for medication discontinuation, and successful pharmacy outcomes of discontinuation (Table 1). A successful pharmacy outcome depended on intent of the prescriber, and in some cases, on the specific reason for medication discontinuation (e.g., adverse drug reaction). A successful pharmacy outcome might require deactivation of more than a single prescription.

<table>
<thead>
<tr>
<th>Prescriber intention</th>
<th>Reason</th>
<th>Successful pharmacy outcome</th>
</tr>
</thead>
<tbody>
<tr>
<td>Prevent a subsequent fill</td>
<td>Adverse drug reaction</td>
<td>Deactivation of all prior prescriptions for this medication; pharmacy notified of allergy</td>
</tr>
<tr>
<td></td>
<td>Alternate therapy, e.g., due to effectiveness or cost</td>
<td>Deactivation of all prior prescriptions for this medication</td>
</tr>
<tr>
<td></td>
<td>Dose adjustment</td>
<td>Deactivation of all prior prescriptions for this medication</td>
</tr>
<tr>
<td></td>
<td>Therapy completed</td>
<td>Deactivation of all prior prescriptions for this medication</td>
</tr>
<tr>
<td>Ensure only one prescription is filled</td>
<td>Duplicate therapy</td>
<td>Deletion or deactivation of one or more prescriptions, retaining a single active prescription</td>
</tr>
<tr>
<td>Medication reconciliation without intent to prevent a fill</td>
<td>Therapy completed but may request refill</td>
<td>Maintenance of prescription on profile as completed but able to request refill</td>
</tr>
</tbody>
</table>
In testing of the pilot scenario, an e-cancellation was only sent when the original e-prescription was written by a CancelRx enabled prescriber from a CancelRx enabled practice (~Table 3). In addition, an e-cancellation could be initiated by a nonprescriber, such as a certified medical assistant, as long as the original prescriber and practice were enabled for CancelRx. By default, e-cancellation messages were sent for all reasons for medication discontinuation, including medication reorder, which discontinues an existing e-prescription and generates a new e-prescription.

Table 2 Results of CancelRx functional testing scenarios

<table>
<thead>
<tr>
<th>Scenario</th>
<th>EHR outcome</th>
<th>Pharmacy outcome</th>
</tr>
</thead>
<tbody>
<tr>
<td>Active e-prescription in EHR and pharmacy</td>
<td>E-prescription written by pilot prescriber</td>
<td>E-cancellation sent to pharmacy</td>
</tr>
<tr>
<td>E-prescription written by nonpilot prescriber</td>
<td>No e-cancellation sent to pharmacy</td>
<td></td>
</tr>
<tr>
<td>Active e-prescription in EHR but not in pharmacy</td>
<td>Prescription transferred</td>
<td>E-cancellation sent to pharmacy</td>
</tr>
<tr>
<td>Prescription reconciled from outside EHR</td>
<td>No e-cancel sent</td>
<td></td>
</tr>
<tr>
<td>No e-prescription</td>
<td>Print and “no print” prescriptions</td>
<td>No e-cancel sent</td>
</tr>
<tr>
<td>Inactive e-prescription</td>
<td>Prescription expired</td>
<td>Unable to test</td>
</tr>
<tr>
<td>Other</td>
<td>Pharmacy does not accept CancelRx</td>
<td>E-cancel message attempted but fails</td>
</tr>
<tr>
<td>Prescription not found</td>
<td>Unable to test</td>
<td></td>
</tr>
</tbody>
</table>

Abbreviation: EHR, electronic health record.
During the 3 months following pilot implementation, Johns Hopkins users sent 463 e-cancellations, 292 resulting from medication discontinuation by pilot participants, and 159 resulting from discontinuation of medications originally prescribed by pilot participants by nonpilot users, consistent with the performance in the test environment. Most (713 of 1005, 70.9%) medication discontinuations by pilot providers did not result in an e-cancellation, most commonly because the prescription had been transferred to another pharmacy, the pharmacy system could not be found by the system or the prescription had been discontinued. In our test environment, the status of the e-cancellation transaction was primarily communicated to the prescriber through the use of in-basket messages. These were generated if the e-cancellation was denied, the e-cancellation was accepted but included a note from the pharmacy, or the pharmacy did not accept e-cancellations. In addition, in the pilot scenario, in-basket messages were also generated when a pilot participant discontinued prescriptions that were not written by a prescriber with e-cancellation capacity. If the prescription had been filled prior to the e-cancellation, the pharmacy software returned this information as a note in the pharmacy response. The pharmacy response was visible in the medication order report in the EHR, but was not visible directly from the medication list; regardless of e-cancellation status, the medication list would display “discontinued.” Based on performance in testing, 73.4% (340/463) of completed e-cancellations from pilot implementation would be expected to generate an in-basket message, including 21 (6.2%) denials and 319/340 (93.8%) approvals with a note from the pharmacy. In addition, we would expect 67 additional in-basket messages from discontinuation of e-prescriptions to pharmacies that did not accept e-cancellation and 258 messages generated by discontinuation of prescriptions written by a nonpilot prescriber.

**Pharmacy Processing and Response**

In most scenarios in our test environment, e-cancellations were automatically matched to an existing e-prescription and presented in the ICQ of the pharmacy management software for review by pharmacy staff. However, manual matching of the e-cancellation in the ICQ with an existing e-prescription was necessary if the e-prescription was in use in a work queue at the time of receipt of the e-cancellation message. When manual matching was required, the prescription remained active and could move forward through the pharmacy workflow until matched to the e-cancellation message. Once a match was completed, either automatically or manually, the pharmacy management system generated a pharmacy response message. If a matching e-prescription could not be found by the system or the prescription had been transferred to another pharmacy, the pharmacy system automatically generated a denial message for that e-cancellation; the e-cancellation did not enter the ICQ and was not seen by pharmacy staff.

Of all 463 e-cancellation messages sent during our pilot, 428 (92.4%) had confirmation of e-cancellation approval by the pharmacy, 21 (4.5%) were denied by the pharmacy, primarily because the prescription had been transferred (18/21, 85.7%), and 14 (3.0%) had no e-cancellation response. Among the 408 e-cancellations received by the pilot Johns Hopkins pharmacy, seven (1.7%) required manual matching by pharmacy staff. Surescripts data were available for time to cancellation response on 413 (89.2%) of 463 e-cancellations. Of these, 21 were not interpretable as they indicated a pharmacy response up to 16 seconds prior to the e-cancellation. In the remaining 392, response time was less than 5 seconds for 95.4% (374/392).

**Communication of e-Cancellation Status within the EHR**

In our test environment, the status of the e-cancellation transaction was primarily communicated to the prescriber through the use of in-basket messages. These were generated if the e-cancellation was denied, the e-cancellation was accepted but included a note from the pharmacy, or the pharmacy did not accept e-cancellations. In addition, in the pilot scenario, in-basket messages were also generated when a pilot participant discontinued prescriptions that were not written by a prescriber with e-cancellation capacity. If the prescription had been filled prior to the e-cancellation, the pharmacy software returned this information as a note in the pharmacy response. The pharmacy response was visible in the medication order report in the EHR, but was not visible directly from the medication list; regardless of e-cancellation status, the medication list would display “discontinued.” Based on performance in testing, 73.4% (340/463) of completed e-cancellations from pilot implementation would be expected to generate an in-basket message, including 21 (6.2%) denials and 319/340 (93.8%) approvals with a note from the pharmacy. In addition, we would expect 67 additional in-basket messages from discontinuation of e-prescriptions to pharmacies that did not accept e-cancellation and 258 messages generated by discontinuation of prescriptions written by a nonpilot prescriber.

**Proactive Risk Assessment**

Our proactive risk assessment revealed the need for improved communications between Johns Hopkins prescribers and pharmacies. We identified seven failure modes with risk prediction numbers up to 32 (of possible 64). Despite ongoing messaging to clinicians that medication discontinuation in Epic did not inform the pharmacy, the greatest risk identified by our stakeholders was prescribers’ lack of communication with pharmacy staff when medications were...
Table 4 Failure modes in CancelRx, mitigation strategies in pilot implementation, and future mitigation opportunities

<table>
<thead>
<tr>
<th>Failure mode</th>
<th>Mitigation strategies for pilot implementation</th>
<th>Recommendations for development</th>
</tr>
</thead>
<tbody>
<tr>
<td>Prescriber does not recognize when an e-cancellation is not sent</td>
<td>• Train prescribers in functionality of CancelRx</td>
<td>• Increase visibility of cancellation status</td>
</tr>
<tr>
<td>Prescriber does not recognize that an in-basket message indicates an e-cancellation failure</td>
<td>• Route in-basket messages to trained RN, • Train prescribers to locate status in order report</td>
<td>• Increase visibility of cancellation status • Reduce in-basket messages that are not actionable</td>
</tr>
<tr>
<td>EHR does not notify prescriber when an e-cancellation is not addressed by a pharmacy</td>
<td>• Monitor frequency</td>
<td>• Notify prescriber when an e-cancellation is not addressed by a pharmacy</td>
</tr>
<tr>
<td>Pharmacist cancels active medication when e-cancellation is sent with a renewal request</td>
<td>• Suppress cancellation with prescription renewals</td>
<td>• Transmit cancellation reason</td>
</tr>
<tr>
<td>User sends e-cancellation in error during medication reconciliation</td>
<td>• Train prescribers in functionality of CancelRx</td>
<td>• Increase visibility of cancellation status • Control by discontinuing user</td>
</tr>
<tr>
<td>Pharmacist matches e-cancellation to wrong prescription</td>
<td>• Monitor frequency</td>
<td>• Reduce manual matches • Provide decision support for manual matches</td>
</tr>
<tr>
<td>Prescriber cannot specify if all prior prescriptions of medication should be discontinued—one to one match only</td>
<td>• Assign responsibility for managing e-cancellation messages to pharmacists</td>
<td>• Allow prescriber to specify if all prior prescriptions of medication should be discontinued • Transmit cancellation reason (e.g., adverse drug event) • Consider transmission to multiple pharmacies</td>
</tr>
</tbody>
</table>

Abbreviations: EHR, electronic health record; RN, registered nurse.

Discussion

In our study, the ability to send electronic messages informing the pharmacy when medications are changed or discontinued addressed a clear unmet need for communication between prescribers and pharmacies. When e-cancellations were sent, over 90% were rapidly approved by pharmacies. However, we identified important limitations to implementation of e-cancellation in our EHR. First, there was no mechanism to send e-cancellation messages for medications that were not e-prescribed in the local EHR, including medications reconciled from outside sources, printed prescriptions, and patient-reported medications. Second, for medications that could generate an e-cancellation, determination of whether an e-cancellation was sent was based on the service level and context of the original prescriber rather than the discontinuing user; as a result, it was difficult to restrict the personnel that could generate e-cancellations (e.g., prescribers only). Third, there was little visibility of the e-cancellation transaction and outcome within a patient’s medical record in the EHR; feedback to prescribers instead relied on in-basket messages, but most of these messages were not actionable. In addition, the CancelRx standard did not communicate the intent of the prescriber or allow for e-cancellation at the drug level (e.g., to prevent dispensing of all prior prescriptions of a medication).

While the current e-cancellation functionality is an important improvement, expansion to include all patient medications and all pharmacies is necessary for patient-centered care and maximal usefulness. Currently, prescribers using Epic who implement CancelRx are only able to e-cancel a subset of their patients’ medications—those e-prescribed within their practice or health system to cancellation-enabled pharmacies. The impact of the restriction to e-prescribed medications was significant in our pilot—over one-third of medications discontinued by pilot prescribers could not be e-cancelled for this reason. However, this will vary by patient and across clinical practices or health systems, depending on the extent to which
patients receive care from outside providers with different EHRs. This limitation might be particularly critical for some clinicians, such as emergency department and primary care clinicians, who might be more likely to discontinue medications prescribed by clinicians from other practices or health systems. The existing SCRIPT standard does not restrict CancelRx to e-prescribed medications in a given EHR. However, sufficient information about the medication would need to be sent in the e-cancellation to accurately identify the patient, prescriber, and dispensing pharmacy.

In comparison, a relatively low proportion of medication discontinuations could not be e-cancelled because receiving pharmacies did not accept e-cancellations. Although several large chains recently began accepting e-cancellations, we anticipate the proportion of successful e-cancellation will be lower in other settings, as the majority of medications in our pilot were e-prescribed to the Johns Hopkins CancelRx-enabled pilot pharmacy. While our EHR vendor added functionality to fax a cancellation to pharmacies that do not accept e-cancellation, this upgrade was not available within our EHR at the start of our pilot. Further understanding of the risks and benefits of fax cancellation and its impact on pharmacy workflows is needed.

Currently, there are no automated safeguards in place to require an e-cancellation to be authorized by a prescriber; as the EHR assesses the service level, or permission, of the original prescriber, rather than the discontinuing user, any staff member with access to remove a medication from the medication list may trigger an e-cancellation. To improve the safety of CancelRx implementation, EHRs should readily allow control of permissions for e-cancellation. Given the current CancelRx implementation in Epic, removal of e-prescriptions from patients’ medication lists should be completed only by prescribers with appropriate training in medication reconciliation.

Given the limitation that some but not all medication discontinuations in the EHR trigger a cancellation and with limited pharmacy adoption of CancelRx, it is critical for prescribers to have clearly visible, real-time information not only on whether an e-cancellation was successfully sent but also if the prescription was successfully deleted or deactivated in the pharmacy system. This feedback would allow the discontinuing prescriber to take appropriate action during the patient encounter if an alternative method of communication to the pharmacy is needed. In our test environment and pilot implementation, discontinuing users did not receive immediate feedback within the patient encounter, but received an in-basket message. However, these notifications were generated for any successful cancellation that included a note from the pharmacy, including successful cancellations for which the pharmacy reported the number of prior fills, when the pharmacy did not accept e-cancellation, and when the pharmacy denied an e-cancellation. Handling these messages requires a separate workflow, creating additional work and potentially leading to delays and omissions in communication to pharmacies.

Our proactive risk assessment identified novel risks with implementation resulting from these limitations in e-cancellation functionality. E-cancellation will transform erroneous discontinuation of an e-prescription in the EHR from a latent error (removal from the medication list) to an active error (prevention of dispensing of a needed medication by the pharmacy), increasing the potential for harm from these errors. The limited visibility of the e-cancellation transaction might contribute to an increased risk of unintended e-cancellations.

We identified a number of potential mitigation strategies for these novel risks, including improvements to implementation of the standard, such as presentation within the EHR to ensure communication of e-cancellation status; reducing manual matching and providing decision support within pharmacy software to reduce errors; and modification of the standard to include transmission of additional information in the e-cancellation, such as the reason for medication discontinuation and whether all prior prescriptions of a medication should be discontinued. Transmission of the reason for discontinuation was identified both by prescribers and pharmacists as an important gap in the current functionality. By providing pharmacists with a greater understanding of prescriber intentions, it might reduce the risk of erroneous e-cancellation, allow pharmacists to more readily identify safety risks (e.g., additional medications that should be discontinued in the case of an ADE), and potentially improve pharmacists’ ability to counsel patients on changes in their medication regimens.

While one-to-one matching between an e-cancellation and e-prescription, as CancelRx is currently implemented, is straightforward and precise, the communication needs between prescribers and pharmacists around medication discontinuation are more complicated. Until there is widespread adoption of e-cancellation, including e-cancellation of prescriptions from sources outside of the local EHR, there will be a backlog of prescriptions that have been discontinued but remain active at the pharmacy. A mechanism that allows the prescriber to indicate intent to discontinue all prior prescriptions of a medication could more quickly eliminate redundancies. In addition, although e-cancellation of prescriptions from sources outside the local EHR would present challenges, this would move us closer to a unified and correct patient medication record and potentially prevent harm when a patient should not continue to receive a medication.

Safe HIT implementation is a critical national patient safety priority.27 The Office of the National Coordinator for Health Information Technology sponsored the development of the SAFER guides28 to serve as a resource for organizations to improve the safety of HIT implementation. Central to these and other HIT safety recommendations are user-centered design, involvement of multiple stakeholders in implementation, identification of ideal workflows, incremental testing within the context of implementation to confirm anticipated performance, identification of unintended consequences, and postimplementation monitoring to ensure the system performs as expected.29–32 Pilot implementation promotes these critical HIT safety recommendations, but incremental implementation within our EHR test environment was technically challenging and created unambiguous restrictions on...
the CancelRx functionality. Improving the ability to conduct controlled, incremental implementation of e-cancellation would allow for safer implementation, particularly in larger health systems where medication reconciliation workflows vary across clinical settings (e.g., inpatient vs. ambulatory). Support for incremental implementation would also allow for institutional learning through a phased rollout and might lead to improved adoption rates, better risk mitigation strategies, and accelerated innovation.33

Best practices for CancelRx implementation within EHRs and by pharmacies will need to be developed on the basis of workflow and outcomes analyses. In some situations, it is not clear if an e-cancellation should be sent. For example, a medication renewal in the EHR discontinues the prior prescription and creates a new prescription for the medication. In the absence of CancelRx, if the new prescription is linked in the pharmacy management software, the new prescription is created for the prior prescription and creates a new prescription for the medication order. In our pilot implementation, we opted not to send e-cancellations with medication renewals due to risk of confusion and because the primary solution to erroneous refill requests should occur within the pharmacy, including correct prescription linkage within the pharmacy system.

CancelRx is an important tool with the potential to decrease errors in medication prescribing and dispensing by facilitating cancellation of erroneous orders immediately upon recognition and communication of changes in medication regimen from prescribers to pharmacies. This function may be complementary with other health information technology (IT) tools to reduce prescribing errors, such as indications-based prescribing34,35 or to facilitate communication between pharmacies and prescribers, such as RxChange, which allows pharmacists to request changes of e-prescriptions from prescribers.36 However, how e-cancellation interacts with these and other functions of e-prescribing within the EHR has yet to be fully determined. CancelRx should be implemented in the context of robust medication reconciliation to reduce the risk of inadvertent cancellation of necessary medications, and questions remain about optimal implementation and workflows. Further understanding of the information needs of key stakeholders in e-prescribing and e-cancellation, including patients, prescribers, and pharmacy staff, could inform the development of future health IT standards and might improve care coordination around medication changes.

Our study benefited from a multidisciplinary collaboration between prescribers, pharmacy staff, health IT experts, and patient safety researchers to systematically and rigorously examine the entire process of e-cancellation. Although this study is limited to a single EHR and pharmacy management software, over 200 million patients have records with this EHR vendor,27,37 illustrating the significance of the issues we identified in this study. Larger scale evaluation is needed to determine how often CancelRx messaging results in successful medication discontinuation at pharmacies and to evaluate its impact on medication errors and ADEs. In addition, future research is needed to examine the performance of CancelRx implementation in other EHRs and pharmacy management systems.

Conclusion
Electronic cancellation messaging, or CancelRx, is an important functionality that has the potential to decrease adverse events due to errors in both medication prescribing and dispensing. However, changes in implementation in our EHR and pharmacy software and enhancements to the CancelRx standard are needed to maximize safety and usability. Further studies are needed to evaluate the impact of e-cancellation on medication safety.

Clinical Relevance Statement
Safe medication discontinuation in ambulatory care is a complex process that entails coordination among multiple stakeholders, including prescribers, pharmacy staff, and patients. Electronic cancellation messaging, or CancelRx, is an important tool that allows prescribers to communicate discontinuation of a medication to the dispensing pharmacy. CancelRx has significant potential to decrease adverse events due to medication errors, but the functionality in our test environment was limited to medications e-prescribed in the local EHR to participating pharmacies.

Multiple Choice Questions
1. Discontinuation of which of the following resulted in an e-cancellation message in the pilot?
   a. Medications reconciled from outside sources, patient reported medications, printed prescriptions, and e-prescribed medications.
   b. Prescriptions generated from within the EHR (printed prescriptions and e-prescribed medications).
   c. E-prescribed medications only.
   d. None of the above.

Correct Answer: The correct answer is option c. In our test environment, the EHR generated an e-cancellation message when a medication was discontinued if the original medication order was an e-prescription. If the receiving pharmacy did not accept e-cancellation transactions, the discontinuing prescriber received an in-basket message indicating that the e-cancellation had failed. No e-cancellation messages were generated for medications on the EHR medication list that were reconciled from outside sources, patient reported, or prescribed within the EHR but printed.
2. Which of the following was not identified as an area for improvement of CancelRx implementation?
   a. Increased visibility of the e-cancellation transaction in the EHR.
   b. Decision support for prescribers.
   c. Decision support for pharmacy staff.
   d. Greater ability to implement CancelRx incrementally in large institutions.

Correct Answer: The correct answer is option b. In our test environment, prescribers did not receive visible feedback on whether an e-cancellation was successfully sent, and if sent the outcome (e.g., successfully removed from the patients’ active prescriptions). Instead, discontinuing prescribers received in-basket messages to communicate transaction outcomes, which required a separate workflow. Given the limitation that some but not all medication discontinuations in the EHR trigger a cancellation and with limited pharmacy adoption of CancelRx, it is critical for prescribers to have clearly visible, real-time feedback to allow them to take timely action if an alternative method of communication to the pharmacy is needed.

Most e-cancellation messages were automatically matched to the appropriate prescription by the pharmacy management software. However, some e-cancellation and e-prescription messages needed to be manually matched by pharmacy staff. Decision support to assist in identification of the correct e-prescription could reduce the risk of error in this process.

Finally, incremental implementation within our test environment was technically challenging and created unintuitive restrictions on the CancelRx functionality. Improving the ability to conduct controlled, incremental implementation of e-cancellation would allow for safer implementation, particularly in larger health systems where medication reconciliation workflows vary across clinical settings (e.g., inpatient vs. ambulatory).

Protection of Human and Animal Subjects
This study did not involve the use of clinical data requiring human subjects review.

Funding
Dr. Pitts was funded by a grant from the National Council for Prescription Drug Programs (NCPDP) Foundation.

Conflict of Interest
None declared.

Acknowledgements
We would like to thank Matthew Lengel, Pharm.D., and Kisten Nolan, RN, for their leadership within the Bartlett pharmacy and practice, and Jim Greene, MJ McMullen, and Shahriar Ahmed from Surescripts for their assistance in the development of the end-to-end test environment and provision of data on Johns Hopkins CancelRx transactions.

References

Fischer S, Rose A. Responsible e-prescribing needs e-discontinuation. JAMA 2017;317(05):469–470


Sittig DF, Classen DC. Safe electronic health record use requires a comprehensive monitoring and evaluation framework. JAMA 2010;303(05):450–451


<table>
<thead>
<tr>
<th>Failure mode</th>
<th>Scenario</th>
<th>Severitya</th>
<th>Detectabilityb</th>
<th>Before CancelRx implementation</th>
<th>After CancelRx implementation</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Frequency</td>
<td>Risk prediction numberd</td>
</tr>
<tr>
<td>No communication with pharmacy attempted</td>
<td>Wrong patient or medication</td>
<td>4</td>
<td>4</td>
<td>2</td>
<td>32</td>
</tr>
<tr>
<td></td>
<td>Duplicate therapy</td>
<td>3</td>
<td>2</td>
<td>4</td>
<td>24</td>
</tr>
<tr>
<td></td>
<td>Alternate medicatione</td>
<td>2</td>
<td>3</td>
<td>3.3</td>
<td>19.8</td>
</tr>
<tr>
<td></td>
<td>Adverse drug eventf</td>
<td>4</td>
<td>2</td>
<td>2</td>
<td>16</td>
</tr>
<tr>
<td></td>
<td>Change in dose or frequencyg</td>
<td>2</td>
<td>2</td>
<td>3.6</td>
<td>14.5</td>
</tr>
<tr>
<td></td>
<td>Wrong pharmacy</td>
<td>1</td>
<td>2</td>
<td>4</td>
<td>8</td>
</tr>
<tr>
<td>Pharmacist misses/misunderstands instructions in “notes to pharmacy”</td>
<td></td>
<td></td>
<td></td>
<td>2</td>
<td>4</td>
</tr>
<tr>
<td>Pharmacist does not read in-basket message prior to medication dispensing</td>
<td></td>
<td></td>
<td></td>
<td>4</td>
<td>3</td>
</tr>
<tr>
<td>Pharmacist misses duplicate alert for medicatione</td>
<td></td>
<td>2.9</td>
<td>3</td>
<td>2</td>
<td>17.3</td>
</tr>
<tr>
<td>Prescriber contacts pharmacist out of workflow on medicatione</td>
<td></td>
<td>2.9</td>
<td>2</td>
<td>2</td>
<td>11.5</td>
</tr>
<tr>
<td>Pharmacist does not hear voicemail prior to medication dispensing</td>
<td></td>
<td>4</td>
<td>2</td>
<td>1</td>
<td>8</td>
</tr>
<tr>
<td>Pharmacist unable to reach prescriber about medication concerne</td>
<td></td>
<td>2.9</td>
<td>1</td>
<td>2</td>
<td>5.8</td>
</tr>
<tr>
<td>User cannot specify that all prior prescriptions of medication should be</td>
<td></td>
<td>3</td>
<td>3</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>discontinued</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Pharmacist matches e-cancellation to wrong prescription</td>
<td></td>
<td>4</td>
<td>3</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>No notification to user by EHR when an e-cancellation is not addressed by</td>
<td></td>
<td>2</td>
<td>4</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>a pharmacy</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>User does not recognize that an in-basket message indicates an</td>
<td></td>
<td>2</td>
<td>2</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>e-cancellation failure</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>User sends e-cancellation in error during medication reconciliationg</td>
<td></td>
<td>NS*</td>
<td>NS</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Pharmacist cancels active medication when e-cancellation is sent with a</td>
<td></td>
<td>NS*</td>
<td>NS</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>renewal requestg</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

*a Frequency categories: 1, unlikely; 2, several times; 3, frequently; 4, continually.

*b Severity categories: 1, less than minor injury; 2, impairment or injury requiring medical intervention; 3, permanent impairment or life-threatening injury; 4, permanent disability or death.

c Detectability categories: 1, certain detection; 2, significant probability of detection; 3, minor probability of detection; 4, cannot detect.

d Risk prediction number is the product of frequency, severity, and detectability.

e Severity, detectability, frequency, and risk prediction number are the geometric mean for three scenarios—for high, medium, and low risk medications.

f Severity, detectability, frequency, and risk prediction number are the geometric mean for two scenarios—patient receiving all medications within Johns Hopkins and patient receiving medications from within and outside of Johns Hopkins.

g This failure mode was identified after the initial proactive risk assessment and was not scored. 

h NS, not scored.